A non-small cell lung cancer clinical trial is recruiting to study benefit of Osimertinib/tagrisso after local ablative therapy
A non-small cell lung cancer clinical trial by Dr. Udayan Guha is recruiting to study the benefit of Osimertinib/tagrisso after local ablative therapy.
Dr. Udayan Guha, investigator in the Thoracic and GI Oncology Branch, is recruiting for a clinical trial for patients with advanced lung adenocarcinoma. Some non-small-cell lung cancers (NSCLC) have mutations in a gene that makes the protein EGFR that may cause tumors to be initially drug sensitive and subsequently develop drug resistance. This study will determine the benefits of giving the drug Osimertinib/tagrisso after local ablative therapy (LAT). Adults 18 and older may be eligible. Contact Laura Wisch, R.N., at 301-594-1827 for more information.
View protocol description.